Changes:RGNX +20.0%ZBIO +12.0%VST +10.0%OKLO +10.0%TLN +1.1%
$VPCATALYST Exiting TSM after catalyst. Adding RGNX and ZBIO for future catalyst.
Changes:GEV +22.0%TLN +17.0%BAC +5.0%PLTR +2.2%WFC +2.0%
Selling FBIO after FDA approval and JPM after results. Buying GEV and TLN for next catalyst.
Changes:PLTR +12.8%TSM +1.0%NFLX +0.5%JPM +0.2%WFC -7.9%
Banking not doing great, diversifying and adding PLTR for next catalyst on Jan 28. Trimming WFC and BAC.
Changes:WFC +15.9%FBIO +10.0%JAZZ -25.0%TSM -0.4%JPM -0.2%
JAZZ sold. Adding WFC for earnings catalyst. Concentrating on FBIO for Jan 14 news. Diversifying from pharma for the moment until better setups available.
Changes:JAZZ +14.0%JPM +0.3%BAC -4.3%FBIO -4.0%NFLX -4.0%
JAZZ received good news just before catalyst on Jan 9. Buying the dip.
Changes:TSM +20.0%NFLX +16.0%JPM +16.0%BAC +15.0%FBIO +6.3%
Rebalancing with focus on Q4 earnings reports. Diversifying from pharma.
Changes:OMER +33.0%JAZZ +25.0%RGNX +10.0%TVTX +0.7%FBIO +0.7%
VNDA approved. CORT received a CRL (complete response letter = negative). Unfortunately CORT is completely erasing our VNDA gains. Redeploying in OMER, JAZZ, and RGNX.
Changes:FBIO +15.0%VRTX +10.0%VNDA +19.4%CORT +8.5%CYTK -50.0%
Selling CYTK after (a positive) FDA approval. Rebalancing and adding FBIO and VRTX for January catalysts.
Changes:CYTK +8.0%VNDA +1.0%TVTX -7.6%CORT -1.5%
Rebalanving to prioritize CYTK, next in line with highest conviction. Selling some TVTX.
Changes:TVTX +15.5%CORT +2.0%CYTK +2.0%VNDA +0.5%INVA -10.0%
Good things come to those who wait, for the FDA approval, sometimes… Anyway, selling MIST and INVA after positive catalyst. Adding TVTX and rebalancing.